Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20009031 | 1.00 | POLB (0.46) | POLBHRH3ALDH1A1KDM4ELMNA | |
| SCHEMBL20009046 | 1.00 | POLB (0.46) | POLBHRH3ALDH1A1KDM4ELMNA | |
| SCHEMBL26948639 | 0.85 | HRH3 (0.36) | POLBHRH3ALDH1A1KDM4EMAPT | |
| SCHEMBL24475624 | 0.85 | HRH3 (0.36) | POLBHRH3ALDH1A1KDM4EMAPT | |
| SCHEMBL26949459 | 0.85 | HRH3 (0.36) | POLBHRH3ALDH1A1KDM4EMAPT | |
| SCHEMBL26241782 | 0.84 | POLB (0.46) | POLBALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL18081296 | 0.84 | POLB (0.46) | POLBALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL14820113 | 0.84 | POLB (0.46) | POLBALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL11602937 | 0.83 | POLB (0.44) | POLBALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL12124972 | 0.82 | POLB (0.43) | POLBALDH1A1KDM4EMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | POLB 241/4885HRH3 203/4885ALDH1A1 3032/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | POLB 241/4885HRH3 203/4885ALDH1A1 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.